John Shin, United States of America

Medtronic Clinical Biostatistics

Presenter of 1 Presentation

ORAL PRESENTATION SESSION

EARLY GLYCEMIC EFFECTS OF THE MINIMED™ ADVANCED HYBRID CLOSED-LOOP (AHCL) SYSTEM AMONG PEDIATRIC (7-17 YEARS) AND ADULT (18-75 YEARS) PERSONS WITH T1D

Abstract

Background and Aims

Clinical trials of the AHCL system demonstrated improved glycemic outcomes.1,2,3 An exploratory analysis investigated how early optimum control was reached in pediatric and adult participants of the MinMed™ AHCL pivotal trial.

Methods

Participants underwent baseline run-in (~2 weeks) with HCL, SAP or CSII therapy followed by a 3-month study phase with the AHCL automated basal and autocorrection bolus therapy. Glycemic outcomes of the run-in and study were compared (including the months 1, 2, and 3 of the study phase) to determine how long it takes to reach glycemic stability and its duration of sustainability.

Results

Tables 1 and 2 show glycemic data for the run-in period, end-of-study phase and months 1, 2, and 3 of the study phase for the pediatric and adult cohorts, respectively. Significant change in mean sensor glucose was observed from run-in to end-of-study and run-in to month 1. Thereafter, no significant changes were observed.

Conclusions

These data suggest that glycemic outcomes in the first month of AHCL use may predict the subsequent two months and permit a shorter time to determine the effectiveness of AHCL in individual patients.

attd 2021 abstract shin table pediatrics final.jpg

attd 2021 abstract shin table adults final.jpg

Hide